Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease

Zhou, Xinyi; Jin, Nan; Wang, Fei; Chen, Baoan

doi:10.1186/s12935-020-01193-z

Cited by 45 publications

(29 citation statements)

References 107 publications

(115 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, the presence of iHPL induced a significant increase of CD4+ and CD8+ naïve T-cell subpopulations compared with stimulated PHA-PBMC, showing higher effects of naïve T-cells than FBS in the co-culture with MSCs. The effect of MSCs on the increase of naïve T cells and the decrease of cytoxic T-cells has already been reported in the literature [ 32 , 33 ], as well as in several clinical trials demonstrating that the administration of MSCs reduced graft versus host disease (GVHD) and ameliorates different autoimmune and/or inflammatory diseases, where the T-cell functional compartment is involved in their pathophysiology [ 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

Inactivated Platelet Lysate Supports the Proliferation and Immunomodulant Characteristics of Mesenchymal Stromal Cells in GMP Culture Conditions

et al. 2020

View full text Add to dashboard Cite

Mesenchymal stromal cells (MSCs) isolated from bone marrow (BM-MSCs) are considered advanced therapy medicinal products (ATMPs) and need to be produced according to good manufacturing practice (GMP) in their clinical use. Human platelet lysate (HPL) is a good GMP-compliant alternative to animal serum, and we have demonstrated that after pathogen inactivation with psoralen, it was safer and more efficient to use psoralen in the production of MSCs following GMP guidelines. In this study, the MSCs cultivated in fetal bovine serum (FBS-MSC) or inactivated HPL (iHPL-MSC) were compared for their immunomodulatory properties. We studied the effects of MSCs on (1) the proliferation of total lymphocytes (Ly) and on naïve T Ly subsets induced to differentiate in Th1 versus Th2 Ly; (2) the immunophenotype of different T-cell subsets; (3) and the cytokine release to verify Th1, Th2, and Th17 polarization. These were analyzed by using an in vitro co-culture system. We observed that iHPL-MSCs showed the same immunomodulatory properties observed in the FBS-MSC co-cultures. Furthermore, a more efficient effect on the increase of naïve T- cells and in the Th1 cytokine release from iHPL was observed. This study confirms that iHPL, used as a medium supplement, may be considered a good alternative to FBS for a GMP-compliant MSC expansion, and also to preserve their immunomodulatory proprieties.

show abstract

Section: Discussionmentioning

confidence: 99%

Inactivated Platelet Lysate Supports the Proliferation and Immunomodulant Characteristics of Mesenchymal Stromal Cells in GMP Culture Conditions

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Dendritic cells (DCs), macrophages, and natural killer (NK) cells are important members of the innate immune response and are regulated by MSCs in various diseases (42)(43)(44). However, their interaction with MSCs is scarcely studied in RA.…”

Section: Immunomodulatory Effect Of Mscs In Ramentioning

confidence: 99%

Immunomodulatory Effects of Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Extracellular Vesicles in Rheumatoid Arthritis

Liu

et al. 2020

Front. Immunol.

113

View full text Add to dashboard Cite

Rheumatoid arthritis (RA) is a chronic autoimmune disease that affects the joints and other organs for which there is currently no effective treatment. Mesenchymal stem cells (MSCs) have therapeutic potential due to their immunomodulatory and differentiation effects. While extensive experimental studies and clinical trials have demonstrated the effects of MSCs in various diseases, MSCs have been found to cause abnormal differentiation and tumor formation. Therefore, extracellular vesicles derived from MSCs (MSC-EVs) are more effective, less toxic, and more stable than the parental cells. MSC-EVs transfer various nucleic acids, proteins, and lipids from parent cells to recipient cells, and thus participate in chronic inflammatory and immune processes. In this review, we summarize the properties and biological functions of MSCs and MSC-EVs in RA. Improvement in our understanding of the mechanisms underlying MSC and MSC-EVs in RA provides an insight into potential biomarkers and therapeutic strategies for RA.

show abstract

“…38,39 The application of bone marrow-derived MSCs, as a regenerative medicine for patients with graft-versus-host disease, an immune-related disease, has been reported. 40…”

Section: Mesenchymal Stem Cellsmentioning

confidence: 99%

“…Intensive studies aimed at establishing clinical applications for MSCs derived from bone marrow and adipose tissue have been performed 38,39 . The application of bone marrow‐derived MSCs, as a regenerative medicine for patients with graft‐versus‐host disease, an immune‐related disease, has been reported 40 …”

Section: Introductionmentioning

confidence: 99%

Platelet production using adipose‐derived mesenchymal stem cells: Mechanistic studies and clinical application

Ono-Uruga

Ikeda

Matsubara

2021

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Megakaryocytes (MKs) are platelet progenitor stem cells found in the bone marrow. Platelets obtained from blood draws can be used for therapeutic applications, especially platelet transfusion. The needs for platelet transfusions for clinical situation is increasing, due in part to the growing number of patients undergoing chemotherapy. Platelets obtained from donors, however, have the disadvantages of a limited storage lifespan and the risk of donor‐related infection. Extensive effort has therefore been directed at manufacturing platelets ex vivo. Here, we review ex vivo technologies for MK development, focusing on human adipose tissue‐derived mesenchymal stem/stromal cell line (ASCL)‐based strategies and their potential clinical application. Bone marrow and adipose tissues contain mesenchymal stem/stromal cells that have an ability to differentiate into MKs, which release platelets. Taking advantage of this mechanism, we developed a donor‐independent system for manufacturing platelets for clinical application using ASCL established from adipose‐derived mesenchymal stem/stromal cells (ASCs). Culture of ASCs with endogenous thrombopoietin and its receptor c‐MPL, and endogenous genes such as p45NF‐E2 leads to MK differentiation and subsequent platelet production. ASCs compose heterogeneous cells, however, and are not suitable for clinical application. Thus, we established ASCLs, which expand into a more homogeneous population, and fulfill the criteria for mesenchymal stem cells set by the International Society for Cellular Therapy. Using our ASCL culture system with MK lineage induction medium without recombinant thrombopoietin led to peak production of platelets within 12 days, which may be sufficient for clinical application.

show abstract

Mesenchymal stem cells: a promising way in therapies of graft-versus-host disease

Cited by 45 publications

References 107 publications

Inactivated Platelet Lysate Supports the Proliferation and Immunomodulant Characteristics of Mesenchymal Stromal Cells in GMP Culture Conditions

Inactivated Platelet Lysate Supports the Proliferation and Immunomodulant Characteristics of Mesenchymal Stromal Cells in GMP Culture Conditions

Immunomodulatory Effects of Mesenchymal Stem Cells and Mesenchymal Stem Cell-Derived Extracellular Vesicles in Rheumatoid Arthritis

Platelet production using adipose‐derived mesenchymal stem cells: Mechanistic studies and clinical application

Contact Info

Product

Resources

About